DDX3: a relevant therapeutic target for lymphoma?

Expert Opin Ther Targets. 2022 Dec;26(12):1037-1040. doi: 10.1080/14728222.2022.2166830. Epub 2023 Jan 10.

Authors

Marion Lacroix^{1

2}, Hugues Beauchemin¹, Tarik Möröy^{1

2

3}

Affiliations

¹ Hematopoiesis & Cancer Research Unit, Institut de recherches cliniques de Montréal, Montréal, QC, Canada.
² Division of Experimental Medicine, McGill University, Montréal, QC, Canada.
³ Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, QC, Canada.

PMID: 36620925
DOI: 10.1080/14728222.2022.2166830

No abstract available

Keywords: B lymphoma; DDX3X; DDX3Y; RNA helicase.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Lymphoma* / drug therapy

Grants and funding

FDN-148372/CIHR/Canada